I suspect that the FDA has advised NP of the minimum number of patients for a potentially approvable interim submission of severe trial data. So it is necessary for NP to delay the submission by a week or two or three. In the meantime, NP will already have potentially rocked the world with approvable data from the m to m trial, a lane that Cytodyn would have to itself. And since coronavirus is not diminishing in its impact on our country any time soon, I am not concerned (from a strictly business point of view) by a few weeks delay in the severe trial data release.